ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised)Zacks Investment Research • 03/05/26
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EUZacks Investment Research • 03/04/26
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett SyndromeBusiness Wire • 03/02/26
Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline KickerSeeking Alpha • 02/28/26
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue GrowthZacks Investment Research • 02/26/26
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating OverviewBusiness Wire • 02/25/26
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 02/18/26
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026Business Wire • 02/04/26
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EUZacks Investment Research • 02/03/26
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European UnionBusiness Wire • 02/02/26
ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/13/26
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum StockZacks Investment Research • 12/22/25
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026Business Wire • 12/18/25
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett SyndromeBusiness Wire • 12/12/25